Why the study?
Does hemodialysis affect the pharmacokinetics of eprosartan in patients with end-stage renal disease compared to healthy volunteers?
Population
19 subjects
Comparison
Single oral dose of eprosartan 400 mg vs Healthy volunteers receiving a single oral dose…
Design
Other, Open-label
Authors
Loading...
Supports no routine post-hemodialysis dose adjustment in ESRD; leaves open optimal individualization amid high PK variability.
Does hemodialysis affect the pharmacokinetics of eprosartan in patients with end-stage renal disease compared to healthy volunteers?
Eprosartan does not require supplemental dosing after hemodialysis, though treatment should be individualized due to pharmacokinetic variability in ESRD patients.
Kovacs et al. (1999) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: